Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen–positive patients §

Authors

  • Teerha Piratvisuth M.D.,

    1. NKC Institute of Gastroenterology and Hepatology Songklanagarind Hospital Prince of Songkla University Hat Yai, Thailand
    Search for more papers by this author
  • Patrick Marcellin M.D.

    1. Service d'Hépatologie Centre de Recherche Biologique Bichat Beaujon (Unité 773) Hôpital Beaujon University of Paris, Clichy, France
    Search for more papers by this author

  • Potential conflict of interest: Dr. Piratvisuth advises, serves on the speakers' bureau of, and received grants from Roche and Novartis. Dr. Piratvisuth advises and serves on the speakers' bureau of GlaxoSmithKline and MSD. Dr. Piratvisuth also serves on the speakers' bureau of Bristol-Myers Squibb.

    Dr. Marcellin serves on the speakers' bureau of, advises, and received grants from Roche, Schering Plough, and Gilead. Dr. Marcellin advises and serves on the speakers' bureau of Bristol-Myers Squibb, Vertex, Novartis, Tibotec, and Intermune. Dr. Marcellin also advises Pharmasset, MSD, Boehringer, Biolex, and Zymogenetics.

  • Editorial support was provided by Dr. Liesje Thomas (Elements Communications, Ltd., Westerham, United Kingdom) and was funded by F. Hoffmann-La Roche (Basel, Switzerland).

  • §

    This work was supported by a research grant from F. Hoffmann-La Roche (Basel, Switzerland).

No abstract is available for this article.

Ancillary